SETUP

ZBH cleared a key resistance level at $97.58 with conviction, gapping up 3.3% on earnings momentum. The stock is now pressing toward the upper half of its 52-week range after bouncing off the $79 lows earlier this year. The breakout is clean and confirmed by live price matching the signal price, but today's bar closed well off the intraday high of $101.53, leaving a notable upper wick. That pullback from highs is a caution flag — buyers showed up but sellers pushed back. Volume came in at 1.38x average, which is supportive but not emphatic for a major breakout.

CATALYSTS

ZBH just beat Q2 estimates and raised full-year guidance, which is the direct fuel for this move. The orthopedic device space benefits from an aging population and a recovering elective procedure environment post-pandemic. Low beta of 0.46 suggests ZBH is a relative safe haven in a choppy macro tape. Next earnings are not until August 2026, so no near-term binary event risk. Insider buying has been heavy and consistent across multiple officers including the CEO and CFO in March 2026, which is a meaningful signal of internal confidence.

RISKS

The signal quality score of 50/100 is the biggest concern here — entry is not early in the move and the stock is technically stretched off its lows. The upper wick on today's bar suggests the $101-102 zone is acting as resistance. The 52-week high sits at $108.29, meaning TP2 is right up against that ceiling where distribution is likely. Risk/reward of 1:1.35 is thin for a setup with this much extension. Tariff or healthcare policy headwinds could weigh on device makers broadly. Any guidance cut or macro softening could reverse this quickly given the magnitude of the YTD move.

CONVICTION: Medium

Solid fundamental backdrop and insider buying support the thesis, but the average signal score, thin R/R, and upper wick on the breakout bar limit confidence in follow-through from current levels.